RPL22

Across TCGA pan-cancer cohorts, RPL22 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPL22 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPL22 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPL22 expression acts as an unfavorable survival marker.

CCRCC, HNSC, and PDAC are the cancer types where RPL22 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.886	1.000	.002	59	view →
HNSC	DFS	Median	All	0.234	0.895	<.001	22	view →
PDAC	DFS	Median	IV	0.214	0.785	.006	16	view →
LSCC	OS	Quartile	All	0.610	1.000	.027	5	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

RPL22–CCRCC (OS)

Open the CCRCC breakdown →